Transient ischemic attack in elderly patient with PHACE syndrome.
Yu Shimizu1, Katsuhiro Tsuchiya1, Hironori Fujisawa1
1Department of Neurosurgery, Kanazawa Medical Center, Kanazawa, Japan.
Surgical Neurology International
|October 23, 2019
Summary
Posterior fossa anomalies, hemangiomas, arterial anomalies, coarctation of the aorta, cardiac defects, and eye abnormalities (PHACE) syndrome can present in older adults. A TIA in an elderly patient may indicate PHACE syndrome, even with rare symptoms like hemiparesis.
Area of Science:
- Neurology
- Pediatric Cardiology
- Vascular Surgery
Background:
- Posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities (PHACE) is a rare congenital anomaly.
- PHACE syndrome presents with a broad spectrum of clinical manifestations, often diagnosed in infancy or childhood.
Related Concept Videos
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
168
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
168
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
199
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
199
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
321
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
321
01:15Drug Dosing: Geriatric Patients
193
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
193
01:30Acute Coronary Syndrome I: Introduction
683
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
683
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
171
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
171